key: cord-0810771-iop6h00p
authors: Roy, Divya; Ramasamy, Ravichandran; Schmidt, Ann Marie
title: Journey to a Receptor for Advanced Glycation End Products Connection in Severe Acute Respiratory Syndrome Coronavirus 2 Infection: With Stops Along the Way in the Lung, Heart, Blood Vessels, and Adipose Tissue
date: 2020-12-17
journal: Arterioscler Thromb Vasc Biol
DOI: 10.1161/atvbaha.120.315527
sha: 6445d7d990e0519fbefc0ed6a66168fe37033c1a
doc_id: 810771
cord_uid: iop6h00p

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has affected millions of people worldwide and the pandemic has yet to wane. Despite its associated significant morbidity and mortality, there are no definitive cures and no fully preventative measures to combat SARS-CoV-2. Hence, the urgency to identify the pathobiological mechanisms underlying increased risk for and the severity of SARS-CoV-2 infection is mounting. One contributing factor, the accumulation of damage-associated molecular pattern molecules, is a leading trigger for the activation of nuclear factor-kB and the IRF (interferon regulatory factors), such as IRF7. Activation of these pathways, particularly in the lung and other organs, such as the heart, contributes to a burst of cytokine release, which predisposes to significant tissue damage, loss of function, and mortality. The receptor for advanced glycation end products (RAGE) binds damage-associated molecular patterns is expressed in the lung and heart, and in priming organs, such as the blood vessels (in diabetes) and adipose tissue (in obesity), and transduces the pathological signals emitted by damage-associated molecular patterns. It is proposed that damage-associated molecular pattern-RAGE enrichment in these priming tissues, and in the lungs and heart during active infection, contributes to the widespread tissue damage induced by SARS-CoV-2. Accordingly, the RAGE axis might play seminal roles in and be a target for therapeutic intervention in SARS-CoV-2 infection.

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing coronavirus disease 2019 (COVID-19) has affected >58 million persons worldwide with nearly 1.4 million deaths, as of late November, 2020. 1 SARS-CoV-2 is an enveloped, nonsegmented positive-sense RNA virus that uses an enzyme RdRp (RNA-dependent RNA polymerase). 2 Cellular infection is dependent on the binding of the SARS-Cov-2 spike protein (S protein) to ACE2 (angiotensin-converting enzyme 2) on the surface of cells; proteases such as the serine protease TMPRSS2 prime the S protein to facilitate entry into the host cells. 3 ACE2 is expressed on a broad range of cells, such as lung alveolar epithelial cells (type I and type II), enterocytes, endothelial cells, smooth muscle cells, the basal cell layer of the epidermis, and proximal tubule cells in the kidney. 4 Among the most prominent and best-described consequences of SARS-CoV-2 are those that affect the lung. In a multi-center study of lung tissue examination at autopsy from patients succumbing to SARS-CoV-2 infection in Italy and New York, frequent tracheobronchitis and significant pulmonary vascular involvement, with noted presence of large vessel thrombi, capillary microthrombi, endothelial swelling, and inflammation was observed. 5 Beyond the lung alveolar epithelial cells, ACE2 is also expressed on such cells as cardiomyocytes and adipocytes. 6, 7 Evidence has linked complications of SARS-CoV-2 to the heart. 8, 9 At presentation of COVID-19 disease, elevated levels of cardiac troponin have been observed, which are indicators of cardiac involvement and harbingers of poor outcome. 10 SARS-CoV-2 may directly infect human cardiomyocytes. 11 Beyond the indirect effects to the heart consequent to the severe respiratory consequences 12 and the yet-to-be-fully explained disorders of coagulation, exemplified in part by high levels of the D-dimer, 13, 14 extensive damage to the heart may ensue from direct infection through necrosis and myocarditis. 9 In other cell types, the expression of ACE2 on adipocytes may link SARS-CoV-2 to obesity, as ACE2 expression in murine adipocytes was regulated by high-fat diet (HFD) feeding. 6 Advanced age and elevation of body mass index have been linked to increased risk for SARS-CoV-2 severity 15 and others reported that dysglycemia, such as in metabolic syndrome or diabetes (type 1 or type 2), also heightens risk for SARS-Cov-2 severity. [16] [17] [18] Collectively, these considerations lead to a key question, are there common threads linking both the enhanced risk for and the severity of SARS-Cov-2 in human infection? Numerous nodes in the pulmonary-cardiac-vascular-immunometabolic SARS-Cov-2 network point to potential roles for the receptor for advanced glycation end products (RAGE) in COVID- 19. In the sections to follow, evidence for a 2-part story for RAGE, both in enhanced risk for and increased severity of SARS-Cov-2 pathobiology will be presented.

This story begins with a brief summary of RAGE. RAGE is a member of the immunoglobulin superfamily of cell surface receptors; it is composed of 5 principal domains. There are 3 extracellular domains, one immunoglobulin (Ig)-like Variable (V) domain followed by 2 Ig-like Constant (C)-type domains (C1 and C2); these are followed by a single transmembrane spanning domain and a short highly charged cytoplasmic domain that contributes to RAGE signaling. 19 RAGE was discovered as a receptor for the advanced glycation end products (AGEs) based on its identification from bovine aortic endothelial cells. 20 AGEs form and accumulate in diverse settings such as in diabetes, aging, oxidative stress, in highly processed foods, renal failure, inflammation, and obesity. [21] [22] [23] [24] [25] Profiling of the expression of human RAGE in adult tissues revealed that RAGE was most highly expressed in the lung, particularly in the type I alveolar epithelial cells, and it has been suggested that RAGE is expressed in the type II alveolar epithelial cells and alveolar macrophages as well. 26, 27 In distinct settings of immunometabolic perturbation, RAGE expression is upregulated in organs such as the heart and coronary arteries, adipose tissue, liver, kidney and the brain, and in immune cells, such as monocytes, macrophages, T and B lymphocytes, and dendritic cells. 24, [28] [29] [30] [31] These considerations and tissue expression patterns for RAGE suggested its involvement in a diverse group of disorders; this concept was supported by the discovery that RAGE was a multi-ligand receptor. Its ability to transduce the effects of multiple members of non-AGE ligand families, such as the S100/calgranulin family, HMGB1 (high-mobility group box 1), amyloid-beta peptide, lysophosphatidic acid, phosphatidylserine, C1q and Mac-1, 32-38 underscored the pleiotropic nature of the ligand-RAGE interaction consequences. It was on account of this multiligand nature of RAGE and its association with chronic disease that led to its inclusion as a damage-associated molecular pattern (DAMP) receptor. 39 Recent reports in COVID-19 have cemented putative links to RAGE and its ligands. First, levels of RAGE ligands S100A8, S100A9, S100A11, and EN-RAGE (S100A12) were highly expressed in lung and serum of fatal versus less severe cases of COVID-19. 40 Second, levels of plasma S100A12 correlated with disease severity and increased bacterial products in patients with COVID-19. 41 Third, serum S100B levels were associated with increased disease severity and COVID-19 score in affected patients. 42 Fourth, in extracellular vesicles, significantly higher levels of S100A12 were observed in patients with severe versus moderate COVID-19. 43 Fifth, higher levels of S100A8/A9 and a distinct DAMP RAGE ligand, HMGB1, were found to associate with higher risk of intensive care unit admission and death in patients with COVID-19. 44 Sixth, HMGB1 was reported to induce NETosis (neutrophil extracellular traps) 45 and to induce ACE2 expression, critical for SARS-CoV-2 entry into cells. 46 Collectively, these considerations, particularly the prominent expression of DAMPs and RAGE in the lung and in alveolar pneumocytes, its role as a DAMP receptor, and their upregulation and activities in COVID-19 and in disorders of immunometabolism pinpoint DAMPs-RAGE as a perfect storm for contributions both to SARS-Cov-2 infection and to conditions that predispose to increased severity of COVID-19. In the sections to follow, evidence will be presented for the concept of the RAGE 2 part story in COVID-19, that is, direct RAGE roles in SARS-CoV-2 infection and in the underlying conditions that predispose to increased risk for COVID-19 severity. Evidence from human subjects and animal models has shown strong links between RAGE and lung disorders, such as allergic airway inflammation and asthma, pulmonary fibrosis, lung cancer, chronic obstructive pulmonary disease, acute lung injury, pneumonia, cystic fibrosis (CF), and bronchopulmonary dysplasia. 47 In CF, studies from the French CF Gene Modifier Study fortified the association between RAGE and the severity of CF, as the AGER promoter variant, −429C, was reported to be associated with increased expression of RAGE and the potential for increased lung inflammation and lung disease. 48 Roles for the RAGE ligand S100A12 have also been implicated in mucin overproduction by epithelial cells in CF in a pathway involving activation of NF-kB (nuclear factor-kappa B). 49 Other studies linked the AGER polymorphism rs2070600T (Ser82) to lung function in smokers. 50 In addition to genetic variants, distinct biomarkers for tracking the activity of the RAGE pathway include the measurement of soluble RAGEs (sRAGE). In addition to cell surface forms of RAGE that bind and transduce the effects of RAGE ligand signaling, soluble forms of RAGE have been identified. In the measurement of total plasma sRAGE in human subjects, ≈80% of the sRAGE is the result of cleavage of the cell surface receptor through the actions of ADAM10 and MMPs (matrix metalloproteinases); the remaining 20% of total sRAGE results from a splice variant of RAGE, called endogenous or esRAGE (endogenous secretory RAGE). 51 Multiple studies have deployed measurements of sRAGE to gauge associations for the RAGE pathway in disorders in which its ligands accumulate and the response to therapeutic intervention. 51 In this context, levels of plasma/serum and bronchoalveolar lavage fluid sRAGE have demonstrated strong associations with acute respiratory disease syndrome and other forms of lung disease. 52, 53 Is there evidence for roles for RAGE in acute lung injuries from animal model studies? Multiple studies have addressed this concept. For example, in an animal model of acute respiratory disease syndrome induced by intratracheal instillation of acid, mice were treated with an anti-RAGE monoclonal antibody or with sRAGE. The authors assessed lung injury by a number of functional, histological, and molecular mediators and reported that both anti-RAGE pathway therapeutics reduced lung injury and alveolar inflammation and improved arterial oxygenation. 54 In another set of studies, cecal ligation and puncture was performed to induce severe polymicrobial sepsis with survival as an end point; mice devoid of Ager and wild-type mice treated with an anti-RAGE antibody displayed significantly higher survival and reduced inflammation and lung pathology versus the respective controls. 55 In that same study, intravenous treatment with Listeria monocytogenes was also induced to mediate severe sepsis; mice devoid of Ager or treated with the anti-RAGE antibody demonstrated improved survival and less organ damage than the respective controls. 55 In distinct work, in lung injury induced by World Trade Center particulate matter, exposure of mice to the particulate matter resulted in striking upregulation of inflammation and reduction of lung function; this was prevented in mice devoid of Ager. 56 Of note, in that study, firefighters exposed during the aftermath of the World Trade Center disaster with the greatest risk for lung injury displayed high levels of circulating sRAGE, in parallel with high levels of CRP (C-reactive protein) and low levels of MMP-9. 56 In summary, RAGE expression in the lung, particularly in alveolar pneumocytes and alveolar macrophages, together with the findings in animal models that deletion or antagonism of RAGE attenuates acute respiratory disease syndrome-like and lung injury pathologies due to distinct stimuli, such as prolific accumulation of DAMPs, may signal potential roles for the receptor in SARS-Cov-2 infection manifestations in the lung. In the cardiopulmonary sphere of dysfunction, the heart is also a direct and indirect target of this infection. Much evidence has shown that RAGE contributes to the cardiac complications of diabetes, ischemia/reperfusion, and viral infections and suggest that the study of this receptor pathway for SARS-Cov-2 impact in the heart is logical.

Injury to the Heart RAGE is expressed in the heart in cells such as cardiomyocytes, vascular cells and resident, and infiltrating immune cells. 57, 58 Global deletion of Ager or pharmacological antagonism of RAGE, either in the isolated perfused heart model (ex vivo) or in the in vivo infarction model (ligation of the left anterior descending coronary artery) imparted protection from the adverse consequences of diabetes or ischemia/reperfusion injury, at least in part through protection from aberrant JAK/ STAT (Janus-associated kinase/signal transducer and activator of transcription) and GSK3 (glycogen synthase kinase 3) signaling. 59, 60 Experiments implicated roles for RAGE in endothelial cells or monocytes/macrophages in these processes. 61 Furthermore, distinct work suggested roles for RAGE in inflammatory heart disease, such as that induced by viruses (such as Coxsackievirus B3) and by autoimmune stimuli. [62] [63] [64] [65] Hence, in the context of cardiopulmonary dysfunction, such as that which might be induced by these above stimuli or SARS-Cov-2, what might be the underlying RAGE-dependent mechanisms? It is known that dying lung cells (endogenous and infiltrated immune cells) and dying cardiac cells may release DAMPs, such as HMGBI and S100/calgranulins, some of which may bind to RAGE and activate highly inflammatory cascades, such as NF-kB, 66 which may exacerbate the early phases of tissue damage. Beyond the DAMPs, recent work has linked both RAGE and SARS-Cov-2 to neutrophil extracellular traps (NETs), which will be considered in the section to follow.

Recent studies underscore the link between NETs and COVID-19 pathology; for example, it was shown that when compared with healthy control subjects, in 32 hospitalized patients with COVID-19, the concentration of NETs was increased in plasma, tracheal aspirates, and lung autopsy tissues. 67 These NETs were derived from SARS-CoV-2-infected neutrophils; in in vitro studies, the NETs mediated lung epithelial cell death, 67 which was proposed to be an important mediator of lung pathology in this disease.

How might these considerations relate to RAGE? A growing body of evidence links RAGE to NET formation and consequences. For example, NETs induce platelet aggregation through RAGE 68 ; NET-derived HMGB1 induces macrophage pyroptosis through RAGE 69 ; disulfide HMGB1 facilitates prothrombotic NET formation via RAGE 70 ; HMGB1 facilitates NET formation in part via RAGE 71 ; RAGE facilitates NET formation in pancreatic cancer 72 ; and platelet-derived HMGB1 facilitates NET formation via RAGE. 73 If and by what means RAGE biology intersects with that of SARS-CoV-2 in the context of NET formation and its prothrombotic and other consequences, especially in the lungs, remains to be tested.

In summary, there are multiple putative mechanisms by which RAGE might play key roles in the pathogenesis of lung-triggered infection, inflammation, and the consequent inflammatory burst that may trigger systemic complications and severe local tissue damage.

Beyond direct RAGE roles in the host response to SARS-CoV-2 infection, it is also plausible that the accumulation of DAMPs in chronic immunometabolic perturbations such as diabetes and obesity may contribute, in part through RAGE, to the enhanced risk and severity of COVID-19. In this part 2 of the putative RAGE story in COVID-19, the following sections will present the evidence supporting this premise.

Studies have shown that diabetes renders patients with SARS-CoV-2 at greater risk of worse prognosis and death. [74] [75] [76] [77] [78] While a myriad of mechanisms may underlie these findings, it is well-established that hyperglycemia perturbs fundamental homeostatic properties of blood vessels that cause increased oxidative stress, higher prothrombotic potential, increased inflammation, including upregulation of adhesion molecules and matrix metalloproteinases, and disruption of the glycocalyx, to name just a few. [79] [80] [81] [82] [83] Some of these, in fact, have parallels in the pathobiology of SARS-CoV-2 infection. In the case of the RAGE axis, the first of the RAGE ligands to be discovered, the AGEs, are increased in diabetes, and their formation is a direct consequence of high levels of blood glucose. AGE-RAGE interaction in endothelial cells enhances vascular permeability, upregulates vascular cell adhesion molecule-1, and increases hypoxia-mediated upregulation of Egr1 (early growth response-1). 20, 84, 85 Critically, beyond AGES, distinct DAMP RAGE ligands, such as HMGB1 and multiple members of the S100/ calgranulin family, are also upregulated in the circulation and tissues in types 1 and 2 diabetes and often associate with the severity of disease and complications. [86] [87] [88] [89] [90] [91] [92] In this context, extensive evidence has indicated that the ligand-RAGE pathway contributes to the pathogenesis of both microvascular and macrovascular complications of diabetes. [93] [94] [95] In experiments using genetic and pharmacological approaches, modulation of RAGE signaling protects from many of the adverse complications of long-term diabetes. [93] [94] [95] In the case of AGE-RAGE dynamics and the direct impact on the vasculature, when mice with targeted expression of dominant negative-RAGE in endothelial cells were bred into the atherosclerosis-prone Apoe-deficient background, decreased atherosclerosis, reduced endothelial inflammation and suppression of proatherogenic signal transduction was observed when compared with control Apoe null mice. 84 In addition to direct vascular cell damage by AGE-RAGE interactions, especially in diabetes, the biology of RAGE has important links to the renin angiotensin system, which is dysregulated in diabetes. 96 ACE2, the receptor for SARS-CoV-2, normally functions to convert Ang II (angiotensin II) into Ang (1-7), thereby opposing the inflammatory and vascular injury-provoking effects of Ang II. 97, 98 In diabetes, reductions in ACE2 favor unchecked actions of Ang II, which may potentiate diabetes-mediated injury. 99, 100 It has been suggested that such dysregulation of the renin angiotensin system in diabetes might contribute to poor outcome in SARS-CoV-2 infection. 101 Previous research linked RAGE to the renin angiotensin system. For example, in spontaneously hypertensive rats, treatment with sRAGE reduced ACE activity, enhanced ACE2 expression, reduced oxidative and inflammatory stress, and limited activation of NF-kB in vascular tissues. 102 Furthermore, others showed that activation of the AT1 receptor by Ang II transactivated the RAGE cytoplasmic domain, leading to proinflammatory effects. 103 Collectively, these considerations suggest that components of the Ang II/ATI and ACE2 axis may be impacted by RAGE, especially in diabetes and, therefore, may contribute to perturbations upon SARS-CoV-2 infection.

Are cells beyond vascular cells affected by hyperglycemia, thereby modulating the impact of SARS-CoV-2 in the infected subject? Indeed, a recent study examined the effects of high levels of glucose on monocytes/macrophage properties in response to this infection. In that work, the authors used publicly available single-cell RNA sequencing data from BAL (bronchoalveolar lavage) fluid of patients with mild and severe COVID-19 and controls, and they identified that several genes associated with IFN (interferon) α/β signaling pathway were upregulated in patients with mild and severe COVID-19 versus controls; this was observed in all 6 clusters of monocytes. 104 It was further shown that SARS-CoV-2 infects peripheral blood monocytes and enhances the expression of ACE2, thereby increasing SARS-CoV-2 infection. SARS-CoV-2-infected monocytes expressed higher levels of a range of proinflammatory factors, such as IFNα, β, and λ and higher levels of TNFα (tumor necrosis factor alpha), IL (interleukin) 1β, and IL6. Importantly, in environments characterized by high levels of glucose, sustained aerobic glycolysis in monocytes, through HIF-1α, promoted viral replication, cytokine production, and mediated the subsequent T-cell dysfunction and lung epithelial cell death observed in SARS-CoV-2-infected lung. These findings thus identify a direct molecular mechanism by which high levels of glucose modulate monocyte/ macrophage metabolism, which imparts significant consequences on inflammation and cellular survival in COVID-19.

On account of the wide range of cellular targets in hyperglycemia, it is likely that multiple insights will continue to emerge regarding the modifying effects of high levels of glucose on the host response to SARS-CoV-2 infection. If and how such perturbations may relate to RAGE signaling remain to be tested.

Adipocytes express ACE2 and ongoing investigations are addressing the question of whether or not adipose tissue is a reservoir for SARS-CoV-2 and, if so, does this serve as a means to amplify systemic viral load? 105, 106 These considerations notwithstanding, it is established that obese adipose tissue may harbor DAMPs, such as AGEs, HMGB1, and S100/calgranulins. 24,107,108 RAGE is expressed in human and murine adipose tissue, in adipocytes as well as in other cells such as immune cells. 24, 109, 110 Mice bearing global deletion of Ager were subjected to HFD feeding; compared with wild-type mice fed HFD, mice with loss of Ager, although consuming equivalent amounts of food, were significantly protected from dietinduced obesity. In parallel, the HFD-fed mice devoid of Ager displayed improved glucose and insulin tolerance. 109 The epididymal visceral adipose tissue (eWAT) of these mice fed the HFD revealed that the total CD11B+/ F4/80+ macrophage content was reduced in the Ager null eWAT versus the wild-type eWAT. Furthermore, the population of CD11B+/F4/80+/CD11C+ cells in the eWAT, which are speculated to be more inflammatory, were also significantly lower in the Ager-deficient versus Ager-expressing eWAT. 109 The mice devoid of Ager and fed the HFD displayed significantly higher energy expenditure than those mice expressing Ager despite no differences in food intake. The underlying RAGE-dependent mechanisms were traced to its expression in adipocytes.

Mice with adipocyte-specific deletion of Ager (in both white and brown adipocytes; using the Adipoq cre recombinase approach) were employed. Ager Flox/Flox Adipoq Cre +/ wt (adipocyte-specific deletion of Ager) and their floxed controls (Ager Flox/Flox Adipoq Cre wt/wt ) were fed a HFD; compared with the floxed control mice, those mice with adipocyte-specific deletion of Ager displayed significant protection from diet-induced obesity and improvements in glucose and insulin tolerance. 110 These mice displayed significantly higher energy expenditure despite no major differences in food intake or physical activity; their brown and subcutaneous white adipose tissues (iBAT [interscapular brown adipose tissue] and iWAT [inguinal white adipose tissue (subcutaneous)], respectively) displayed significantly higher expression of genes linked to thermogenesis such as Ucp. 110 Further, the eWAT of the adipocyte Ager-deleted mice fed HFD experiments traced the mechanism to RAGE ligand-dependent downregulation of protein kinase A activities on lipolysis and regulation of thermogenic gene programs. 110 These intriguing findings uncovered potential innate functions for RAGE in conservation of energy mechanisms; in the lean state, the quantity of DAMPs and pathological ligands in adipose tissue is low. However, in over-nutrition and obesity, the hoarding of energy in fat cells appears to correspond to plentiful accumulation of proinflammatory ligands. If and how the basal upregulation of RAGE ligands including the DAMPs in adipose tissue depots might raise the risk for severity of infection by viruses such as SARS-Cov-2 remains to be tested.

It is notable that obesity may not only portend adverse outcomes in SARS-Cov-2 but in other viral infections, as well. It was reported that during the influenza A subtype H1N1 pandemic, obesity was found to correlate with worse outcome and death compared with lean persons based on the stratification by body mass index. 111 Hence, at least in a subset of viral infections, the increased adipose and immune cell inflammation may, by yet to be defined mechanisms, facilitate excessively exuberant host responses to discrete infections, thereby leading to adverse clinical outcomes. If and how DAMP accumulation, and potential roles in such mechanisms as trained immunity, may contribute to such vulnerability needs to be studied.

In summary, the 2 part hypothesized story for RAGE in both severity of and enhanced risk for more severe COVID-19 was recently buttressed by new insights into roles for RAGE in interferon biology, as presented in the section to follow.

An unexpected facet of RAGE biology was recently unearthed in studies probing mechanisms by which RAGE suppressed regression of diabetic atherosclerosis in a murine model. 112 In parallel with accelerated regression of atherosclerosis in diabetic mice devoid of Ager, RNA sequencing studies revealed that Ager null macrophages retrieved from the regressing atherosclerotic plaques demonstrated significant reduction in the interferon signaling pathway, and, in particular, in expression of Irf7. In in vitro studies, in primary bone marrow derived macrophages, RAGE ligands or serum from Western dietfed mice devoid of the low density lipoprotein receptor (Ldlr; 2%) upregulated Irf7 in a manner that was reduced by genetic deletion of Ager or by siRNA-targeted reduction of Ager in wild-type bone marrow derived macrophages. Furthermore, the plasma of diabetic Ager null mice undergoing regression of diabetic atherosclerosis revealed significantly lower levels of IFN-γ versus levels observed in the control wild-type diabetic mice. 112 IRF7 (interferon regulatory factor 7) is considered a master regulator of the type 1 interferon response, as mice devoid of Irf7 display severe vulnerability to viral infections and reduction in IFNα/β. 113 IRF7 is also expressed on nonimmune cells, such as smooth muscle cells. 114, 115 In the context of SARS-CoV-2, ongoing research is revealing that the biology of interferon and type 1 IFN immunity is complex. It has been suggested that patients with severe and life-threatening COVID-19 display inborn errors of type 1 IFN immunity. 116 An enrichment of rare variants predicted to cause loss of function at 13 human loci known to govern TLR3 (tolllike receptor 3) and IRF7-dependent type 1 IFN immunity to influenza virus was noted in 659 patients with life-threatening severe COVID-19 pneumonia when compared with 534 subjects with very mild or asymptomatic SARS-CoV-2 infection. In vitro, human fibroblasts bearing these mutations displayed increased vulnerability to SARS-CoV-2 infection. 116 In other studies, it was shown that 101 of 987 patients with lifethreatening COVID-19 displayed neutralizing antibodies against IFN-ω (and in some cases IFN-α) or both. It was reported that these auto-antibodies neutralized the ability of the relevant IFNs to block SARS-CoV-2 infection in vitro. 117 Collectively, these findings suggest beneficial and critical roles for IFNs in the response to SARS-CoV-2; the situation, however, may be more complex and requires further investigation.

Recent evidence suggests that there may be distinct time-dependent differences in the roles of IFNs in SARS-CoV-2 infection. It is possible that whereas early rises in IFNs may be protective, later stage rises in IFNs may actually cause hyperinflammatory responses in part via the accumulation of monocytes and macrophages in the lung. 118,119 Hence, despite the success of a number of recent IFN-β trials, it was noted that care needed to be taken to consider issues of timing and patients subgroups. 119 Insights into this complexity emerged from studies in mouse models.

Channappanavar et al 120 showed that delayed IFN1 signaling in SARS-CoV-infected mice resulted in the pathological accumulation of inflammatory monocytes/ macrophages and consequent elevation of lung cytokine levels, vascular leakage and impaired virus-specific T-cell responses. In mice expressing human ACE2 (adenovirus), these authors showed that whereas IFNs did not mediate major changes in viral replication, they did cause significant pathological activation of immune cells. 121 The authors, using wild-type mice and mice devoid of the IFNα receptor (Ifnar −/− ) or devoid of both Irf3/Irf7, suggested that type 1 IFNs may be important drivers of pathological sequelae in SARS-CoV-2 infection. Perhaps, it is all about the timing, the distinct cellular milieus, and the potential priming effects of preexisting and comorbid conditions associated with increased severity of COVID-19. It will be essential to dissect these potential timedependent effects of IFNs in COVID-19 to maximize the possible benefits of IFN treatment for this disease.

These concepts lead to the premise that if, how, and in what settings the DAMP receptor RAGE might modulate the timing of IFN responses, perhaps through IRF7, remains to be tested. In this context, studies have tested roles for RAGE in viral infections and revealed complex relationships. In influenza A infection, deletion of Ager resulted in improved survival, improved viral clearance, and enhanced T-cell responses and neutrophil activation. 122 In Newcastle disease virus infection, HMGB1-RAGE interaction increased cytokine production in cellular models. 123 In cellular models of the blood brain barrier, RAGE and CC7 enhanced the transmigration of Zika-infected monocytes through the barrier. 124 In cellular models, RAGE, along with TLRs 2 and 4, promoted cytokine production induced by porcine reproductive and respiratory syndrome virus. 125 Mice devoid of Ager or mice treated with sRAGE were protected from respiratory syncytial virus A2 strain-induced weight loss and inflammation 126 ). In a distinct study, mice devoid of Ager displayed impaired antiviral immunity when infected with pneumonia virus of mice strain J3666, which is a murine analogue of RSV (respiratory syncytial virus). 127 The reasons for these divergent RAGE-dependent responses were not elucidated from those studies.

However, antiviral responses are also mediated through distinct DAMP receptors, the TLRs. In the section to follow, the interplay between RAGE and TLRs in the context of COVID-19 is considered.

The discovery that RAGE ligands upregulated Irf7 in bone marrow derived macrophages raises the key issue of possible links between RAGE and the TLRs in the response to SARS-CoV-2 infection. Infection of the human lung epithelial cell line, A549, with SARS-CoV-2 upregulated a number of pathways; by gene ontology analysis, upregulation of the TLR pathway was observed. 128 Among the genes identified relevant to this pathway were Irf7, Ccl5, Stat1, Cxcl8, Tlr8, and Fos. TLRs transmit the biological signals emitted by pathogenassociated molecular patterns, such as those relevant to viral infections. 129 Although much work needs to be done to dissect the potential specific contributions of the multiple members of the TLR family, it is speculated that TLR7 may be key to driving the effects of single stranded RNA, relevant to SARS-CoV-2, which leads to activation of the type I IFN response. 130 In in vitro studies, it was suggested that incubation of human lung macrophages with SARS-CoV-2 triggered TLR4-mediated cytokine release. 131 Full elucidation of the beneficial versus antagonist roles for specific TLRs may lead to novel therapeutic opportunities for COVID-19.

In this context, as discussed above, RAGE also activates NF-kB and plays roles in macrophages in regulation of IRF7. It was previously shown that RAGE may bind to DNA. 132 In other studies, it was reported that RAGE bound RNA and that RAGE enhanced cellular RNA uptake into endosomes. 133 With respect to intersection with the TLRs, it was also shown that RAGE increased the sensitivity of the single strand RNA sensing TLRs, such as TLR7, 8, and 13. 133 Atop these considerations that both RAGE and TLRs may bind DNA and RNA, additional molecular bridges between these 2 pathways ensue from the ability of both RAGE and TLRs to bind HMGB1. 134 Hence, it is likely that there may be relationships between RAGE and TLRs in the lung and other tissues such as the heart, upon infection and contact with SARS-CoV-2. It is important to point out that nature and evolutionary forces may have had divergent expectations and plans for the functions of TLRs versus RAGE, or, perhaps RAGE evolved to complement and fortify at least some of the functions of the TLRs. On the one hand, the TLRs may be traced to orthologs in Drosphila. 135 In contrast, AGER, located on chromosome 6 in the MHC (major histocompatibility complex) III humans, 136 first appeared in Laurasiatheria. 137 Laurasiatheria is a superorder of placental mammals that is part of the larger group of mammals classified as Eutheria, which are mammalian clades that date to 160 million years ago. 138 In the Eutherians, a key property is the expression of UCP1 (uncoupling protein 1), which is linked to nonshivering thermogenesis. 139 Do the distinct origins of the TLR and RAGE networks have implications for responses to viral infections? At this time, in SARS-CoV-2 infection, it is clear that much work needs to be done to identify if interactions between RAGE and the TLRs exist and the timing of their involvement in priming and active infection in COVID-19.

Studies in animal models are likely to shed light on the nature of the host responses that orchestrate the (patho) biological response to SARS-CoV-2 infection. This will be considered in the section to follow.

Multiple species of animals have been considered for the study of SARS-CoV-2 infection; in naturally vulnerable species such as hamsters, ferrets, cats, and nonhuman primates, disease associated with this infection is often mild and not progressive but, in some species, age-related increases in severity have been observed. 140 Efforts have been made to study SARS-CoV-2 infection in mice models on account of the more ready availability of mouse models for testing roles for specific genes. As the murine ACE2 may have reduced affinity for the SARS-CoV-2 Spike protein, humanized models of the ACE2 have been generated to overcome this limitation. [141] [142] [143] Examples include clustered regularly interspaced short palindromic repeats/clustered regularly interspaced short palindromic repeat (CRISPR-Cas)mediated knock-in of the hACE2 (human angiotensin-1 converting enzyme 2) 141 ; expression of hACE2 under control of the murine Ace2 promoter 142 ; and K18 transgenic hACE2 mouse, in which hACE2 is under control of the cytokeratin-18 gene promoter. 143 In each case, there are pros and cons; for example, in the K18-hACE2 mouse, although SARS-CoV-2-infected animals display weight loss, severe pulmonary involvement and mortalities, the expression of hACE2 is artificially driven and not under the natural control mechanisms for the gene. 143 These considerations notwithstanding, such murine models, may facilitate understanding of the mediators of injury directly upon COVID-19 infection and may aid in uncovering how underlying conditions such as obesity or diabetes may exacerbate the impact of SARS-CoV-2 infection in the host. Such knowledge may then lead to targets amenable to therapeutic testing. In this context, based on the hypothesized part 1 (direct infection) and part 2 (conditions amplifying COVID-19 severity) roles for RAGE, the potential benefits of antagonism of RAGE may be probed. In the section to follow, means to antagonize RAGE will be considered.

Multiple efforts have been made to target RAGE using small molecules antagonists of the extracellular domains, antibodies, aptamers, and sRAGEs, as examples. 51, [144] [145] [146] However, the extracellular domains of RAGE are complex; they are composed of 3 extracellular Ig-like domains that bind the ligands of RAGE at distinct sites within the V and C1 and C2 domains. 147, 148 Accordingly, it is possible that blockade of RAGE at discrete sites on these extracellular domains may fail to capture the pathobiology of all of its relevant ligands. Toward this end, targeting RAGE through blockade of its cellular signaling pathways has been proposed as a more comprehensive strategy.

The cytoplasmic domain or tail of RAGE, although essential for RAGE signaling, requires its interaction with adapter molecules to transduce the consequences of RAGE ligand extracellular binding and to initiate signaling cascades. In this context, the cytoplasmic domain or tail of RAGE binds to the FH1 (formin homology 1) domain of DIAPH1 (Diaphanous 1) and DIAPH1 is important for RAGE-mediated signaling. 149 The specific amino acids in cytoplasmic domain or tail of RAGE required for this interaction are R5Q6; upon their mutation to alanine residues, NMR-based spectroscopic evidence of their interaction is attenuated and in smooth muscle cells bearing the A5/A6 mutant, RAGE ligandtriggered signal transduction (activation of AKT [protein kinase B]) was attenuated versus that observed in the R5/Q6 wild-type construct. 150 This interaction site provided a potential opportunity for the development of small molecule antagonists; screening of a >59 000 compound small molecule library resulted in the identification of 13 small molecules that blocked cytoplasmic domain or tail of RAGE-DIAPH1 interaction. 151 In cellular systems and in vivo, after infusion of RAGE ligands into wild-type mice, administration of small molecule antagonists suppressed inflammation in liver and kidney tissue compared with mice receiving vehicle. 151 The observation that the RAGE-DIAPH1 axis represents a key signal transduction scaffold that is amenable to therapeutic interruption, unveils an entirely new set of hypotheses regarding potential roles for this signaling axis, RAGE-DIAPH1, in vascular and immune cell biology. To date, multiple studies in mice devoid of Diaph1 reveal striking similarities to the findings observed in Ager null mice, thereby linking these 2 pathways in biological systems beyond NMR spectroscopy and cell culture to rigorous hypothesis-testing in vivo. [152] [153] [154] In summary, given the availability of a range of animal model species of SARS-CoV-2 infection, the targeting of extracellular or intracellular RAGE in SARS-CoV-2 infection is feasible.

Research has advanced knowledge of RAGE, from its earliest identified high level of basal expression in the lung, to its role as a conduit for transducing the effects of AGEs and other DAMPs, to one whose intracellular domain engages a formin, DIAPH1, thereby connecting RAGE to signaling scaffolds mediating biological and pathobiological functions through the actin cytoskeleton, Rho GTPase signaling and regulation of SRF (serum response factor)-dependent genes-each key pieces in vascular and immune cell perturbations (Figure) . [155] [156] [157] Atop these observations, the recent discovery of RAGE ligand-dependent regulation of IRF7 in macrophages raises new and unanticipated possibilities-is RAGE involved in the host response to viral infections; does DIAPH1 participate; does RAGE-dependent activation of NF-kB and IRF7 contribute to the cytokine barrage after SARS-CoV-2 infection; might antagonism of RAGE/DIAPH attenuate the aggressive inflammatory barrage triggered at least in some patients infected with COVID-19?

Finally, as clinical studies have identified that disorders of metabolism (diabetes and obesity) amplify the risk for severe manifestations of COVID-19, is it plausible that the increased production and accumulation of DAMPs in metabolic and vascular tissues, and through their interactions with RAGE, raise basal signaling and inflammatory stress via circulating immune cell-host cell communications, thereby priming the tissues throughout the diabetic or obese host, thus amplifying the response to SARS-Cov-2 infection? Undoubtedly, optimal prevention and control of SARS-CoV-2 infection will require a multi-pronged approach. If and to what extent RAGE might be a key component within the COVID-19 armamentarium of therapeutic strategies is under investigation as the journey continues.

Received October 24, 2020; accepted November 30, 2020. 

Recent studies from SARS-CoV-2-infected human subjects have demonstrated that elevation of damage-associated molecular patterns (DAMP) ligands of RAGE, such as HMGB1, S100A8, S100A9, S100A11, S100A12, and S100B in the lung tissue, and plasma/serum are associated with disease severity and risk of death. Hence, in active infection, in part I of the hypothesized RAGE response in acute infection (top), these DAMP ligands of RAGE may exacerbate the local responses to infection in organs such as the lung and heart, leading to severe cell stress/ death. The known sequelae of RAGE activities, in part through the actions of NF-kB (nuclear factor-kappa B), lead to endothelial dysfunction (permeability, prothrombotic and proinflammatory state); immune cell activation, oxidative stress, and upregulation of distinct factors such as EGR1 (early growth response 1), which coordinates much of the adverse responses to hypoxia and ischemia. The recent observation that RAGE ligands upregulate IRF7 (interferon regulatory factor 7) in immune cells suggests that DAMP RAGE ligands might aggravate disease in SARS-CoV-2 infection. Within the sphere of RAGE biology, many of these same DAMP ligands also accumulate in chronic inflammatory and metabolic disorders. In part 2 of the hypothesized RAGE priming mechanisms in diabetes/hyperglycemia and obesity (bottom), the inexorable accumulation of advanced glycation end products (AGEs) and other DAMP RAGE ligands relevant to cardiometabolic perturbation may prime the organs for amplification of inflammatory and tissue-damaging mechanisms upon SARS-CoV-2 infection. Hence, blockade of RAGE, during immunometabolic priming in diabetes/obesity, or during active SARS-CoV-2 infection, might be efficacious in tempering the damage from acute infection and in preventing diabetes/obesity-mediated amplification of coronavirus disease 2019 (COVID-19) severity. These hypotheses are open questions amenable to investigation. EC indicates endothelial cell; and TLR, toll-like receptor.

Coronavirus Resource Center 2020

Chapter 10 -polymerases of coronaviruses: structure, function, and inhibitors

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis

Covid-19 pulmonary pathology: a multi-institutional autopsy cohort from italy and new york city

ACE2 is expressed in mouse adipocytes and regulated by a high-fat diet

Cell type-specific expression of the putative SARS-CoV-2 receptor ACE2 in human hearts

COVID-19 and the heart and vasculature: novel approaches to reduce virus-induced inflammation in patients with cardiovascular disease

COVID-19 can affect the heart

Elevated troponin in patients with coronavirus disease 2019: possible mechanisms

SARS-CoV-2 infects and induces cytotoxic effects in human cardiomyocytes

Clinical, laboratory and radiological characteristics and outcomes of novel coronavirus (SARS-COV-2) infection in humans: a systematic review and series of meta-analyses

Coagulation abnormalities and thrombosis in patients infected with SARS-CoV-2 and other pandemic viruses

Prevalence and outcomes of D-dimer elevation in hospitalized patients with COVID-19

Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease

Exploring diseases/traits and blood proteins causally related to expression of ACE2, the putative receptor of SARS-CoV-2: a mendelian randomization analysis highlights tentative relevance of diabetes-related traits

Endothelial activation and dysfunction in metabolic syndrome, type 2 diabetes and coronavirus disease 2019

Pisa COVID-19 Study Group. Hyperglycemia at hospital admission is associated with severity of the prognosis in patients hospitalized for COVID-19: the pisa COVID-19 study

Soluble RAGE: therapy and biomarker in unraveling the RAGE axis in chronic disease and aging

Protein glycation: a firm link to endothelial cell dysfunction

Dietary advanced glycation end products and their role in health and disease

Pathways of the Maillard reaction under physiological conditions

The role of methylglyoxal and the glyoxalase system in diabetes and other age-related diseases

Nε-(carboxymethyl)lysine-receptor for advanced glycation end product axis is a key modulator of obesity-induced dysregulation of adipokine expression and insulin resistance

The myeloperoxidase system of human phagocytes generates Nepsilon-(carboxymethyl)lysine on proteins: a mechanism for producing advanced glycation end products at sites of inflammation

Receptor for advanced glycation endproducts (RAGE) exhibits highly differential cellular and subcellular localisation in rat and human lung

Type II alveolar epithelial cells in lung express receptor for advanced glycation end products (RAGE) gene

Morphologic findings of coronary atherosclerotic plaques in diabetics: a postmortem study

Endogenous formation of Nε-(carboxymethyl)lysine is increased in fatty livers and induces inflammatory markers in an in vitro model of hepatic steatosis

AGE-RAGE stress: a changing landscape in pathology and treatment of Alzheimer's disease

Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease

RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides

The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system

RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease

Receptor for advanced glycation end products binds to phosphatidylserine and assists in the clearance of apoptotic cells

Lysophosphatidic acid targets vascular and oncogenic pathways via RAGE signaling

RAGE binds C1q and enhances C1q-mediated phagocytosis

A novel pathway of HMGB1-mediated inflammatory cell recruitment that requires Mac-1-integrin

Inside, outside, upside down: damage-associated molecular-pattern molecules (DAMPs) and redox

Transcriptional and proteomic insights into the host response in fatal COVID-19 cases

Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans

Serum S100B protein as a marker of severity in Covid-19 patients

The potential role of extracellular vesicles in covid-19 associated endothelial injury and pro-inflammation. medRxiv

Elevated serum levels of S100A8/A9 and HMGB1 at hospital admission are correlated with inferior clinical outcomes in COVID-19 patients

Neutrophil extracellular traps (NETs) and damage-associated molecular patterns (DAMPs): two potential targets for COVID-19 treatment

Genome-wide crispr screens reveal host factors critical for SARS-COV-2 infection

All the "RAGE" in lung disease: The receptor for advanced glycation endproducts (RAGE) is a major mediator of pulmonary inflammatory responses

AGER -429T/C is associated with an increased lung disease severity in cystic fibrosis

S100A8, S100A9 and S100A12 activate airway epithelial cells to produce MUC5AC via extracellular signal-regulated kinase and nuclear factor-κB pathways

The Ser82 RAGE variant affects lung function and serum RAGE in smokers and sRAGE production in vitro

Soluble RAGEs -prospects for treating & tracking metabolic and inflammatory disease

Soluble receptor for advanced glycation end products (sRAGE) is present at high concentrations in the lungs of children and varies with age and the pattern of lung inflammation

Levels of soluble receptor for advanced glycation end products in bronchoalveolar lavage fluid in patients with various inflammatory lung diseases

RAGE inhibition reduces acute lung injury in mice

Inhibition of the RAGE products increases survival in experimental models of severe sepsis and systemic infection

Receptor for advanced glycation endproducts and World Trade Center particulate induced lung function loss: a case-cohort study and murine model of acute particulate exposure

Receptor for advanced glycation end products (RAGE) and implications for the pathophysiology of heart failure

Receptor for advanced-glycation end products: key modulator of myocardial ischemic injury

RAGE modulates myocardial injury consequent to LAD infarction via impact on JNK and STAT signaling in a murine model

RAGE modulates hypoxia/reoxygenation injury in adult murine cardiomyocytes via JNK and GSK-3beta signaling pathways

RAGE and modulation of ischemic injury in the diabetic myocardium

Pathogenic role of the damage-associated molecular patterns s100a8 and s100a9 in coxsackievirus b3-induced myocarditis

Endothelial RAGE exacerbates acute postischaemic cardiac inflammation

Critical role of RAGE and HMGB1 in inflammatory heart disease

Blocking the receptor for advanced glycation end product activation attenuates autoimmune myocarditis

Extracellular HMGB1: a therapeutic target in severe pulmonary inflammation including COVID-19?

Sarscov-2-triggered neutrophil extracellular traps mediate covid-19 pathology

Chloroquine reduces hypercoagulability in pancreatic cancer through inhibition of neutrophil extracellular traps

Neutrophil extracellular traps promote macrophage pyroptosis in sepsis

Disulfide HMGB1 derived from platelets coordinates venous thrombosis in mice

High-mobility group box 1 potentiates antineutrophil cytoplasmic antibody-inducing neutrophil extracellular traps formation

The receptor for advanced glycation end products (RAGE) enhances autophagy and neutrophil extracellular traps in pancreatic cancer

Activated platelets present high mobility group box 1 to neutrophils, inducing autophagy and promoting the extrusion of neutrophil extracellular traps

COVID-19 in people with diabetes: understanding the reasons for worse outcomes

China Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China

Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Prevalence and impact of diabetes among people infected with SARS-CoV-2

Platelets and diabetic vascular disease

Microcirculation and diabetes

Glucose and diabetic vascular disease

The cellular and molecular mechanisms of diabetic complications

What's the RAGE? The receptor for advanced glycation end products (RAGE) and the dark side of glucose

Vascular and inflammatory stresses mediate atherosclerosis via RAGE and its ligands in apoE-/-mice

Advanced glycation end product (AGE)-receptor for AGE (RAGE) signaling and up-regulation of Egr-1 in hypoxic macrophages

Increased plasma S100A12 levels are associated with diabetic retinopathy and prognostic biomarkers of macrovascular events in type 2 diabetic patients

The protein S100A4 as a novel marker of insulin resistance in prepubertal and pubertal children with obesity

Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein

Increased plasma S100A12 (EN-RAGE) levels in patients with type 2 diabetes

Plasma HMGB-1 levels in subjects with obesity and type 2 diabetes: a cross-sectional study in China

Higher plasma high-mobility group box 1 levels are associated with incident cardiovascular disease and allcause mortality in type 1 diabetes: a 12 year follow-up study

Alarmin high-mobility group B1 (HMGB1) is regulated in human adipocytes in insulin resistance and influences insulin secretion in β-cells

Role of advanced glycation endproduct (AGE)-receptor for advanced glycation endproduct (RAGE) axis in cardiovascular disease and its therapeutic intervention

Glycation & the RAGE axis: targeting signal transduction through DIAPH1

Emerging targets for therapeutic development in diabetes and its complications: the RAGE signaling pathway

Renin-angiotensin system in diabetes

A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase

The novel angiotensin-converting enzyme (ACE) homolog, ACE2, is selectively expressed by adult Leydig cells of the testis

Interaction of diabetes and ACE2 in the pathogenesis of cardiovascular disease in experimental diabetes

Role of angiotensin-converting enzyme 2 (ACE2) in diabetic cardiovascular complications

SARS-CoV-2 infections and ACE2: clinical outcomes linked with increased morbidity and mortality in individuals with diabetes

Soluble receptor for advanced glycation end products mitigates vascular dysfunction in spontaneously hypertensive rats

Transactivation of RAGE mediates angiotensin-induced inflammation and atherogenesis

Elevated glucose levels favor SARS-CoV-2 infection and monocyte response through a HIF-1α/glycolysis-dependent axis

Obesity and diabetes as comorbidities for covid-19: underlying mechanisms and the role of viral-bacterial interactions

Is adipose tissue a reservoir for viral spread, immune activation, and cytokine amplification in coronavirus disease 2019? Obesity (Silver Spring)

HMGB1, an innate alarmin, plays a critical role in chronic inflammation of adipose tissue in obesity

S100 proteins in obesity: liaisons dangereuses

RAGE regulates the metabolic and inflammatory response to high-fat feeding in mice

A receptor of the immunoglobulin superfamily regulates adaptive thermogenesis

Association between H1N1 infection severity and obesity-adiponectin as a potential etiologic factor

Rage impairs murine diabetic atherosclerosis regression and implicates irf7 in macrophage inflammation and cholesterol metabolism

IRF-7 is the master regulator of type-I interferon-dependent immune responses

Interferon regulatory factors: at the crossroads of immunity, metabolism, and disease

Interferon regulatory factor 7 protects against vascular smooth muscle cell proliferation and neointima formation

Inborn errors of type I IFN immunity in patients with life-threatening covid-19

Auto-antibodies against type I IFNS in patients with life-threatening covid-19

Dysregulation of type I interferon responses in COVID-19

The type I interferon response in COVID-19: implications for treatment

Dysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice

Mouse model of SARS-COV-2 reveals inflammatory role of type i interferon signaling

Receptor for advanced glycation end products is detrimental during influenza A virus pneumonia

Newcastle disease virus infection triggers HMGB1 release to promote the inflammatory response

RAGE and CCR7 mediate the transmigration of Zika-infected monocytes through the blood-brain barrier

Porcine reproductive and respiratory syndrome virus infection triggers HMGB1 release to promote inflammatory cytokine production

Opposing roles of membrane and soluble forms of the receptor for advanced glycation end products in primary respiratory syncytial virus infection

Rage deficiency predisposes mice to virus-induced paucigranulocytic asthma

Identification and classification of differentially expressed genes reveal potential molecular signature associated with SARS-CoV-2 infection in lung adenocarcinomal cells

Involvement of ERK, p38 and NF-kappaB signal transduction in regulation of TLR2, TLR4 and TLR9 gene expression induced by lipopolysaccharide in mouse dendritic cells

The toll for trafficking: toll-like receptor 7 delivery to the endosome

Toll-like receptors and Covid-19: a two-faced story with an exciting ending

RAGE is a nucleic acid receptor that promotes inflammatory responses to DNA

RAGE enhances TLR responses through binding and internalization of RNA

HMBG1 mediates ischemia-reperfusion injury by TRIF-adaptor independent Toll-like receptor 4 signaling

Inflammation, metaflammation and immunometabolic disorders

Adaptive evolution of the MHC class III-encoded receptor RAGE in primates and murine rodents

The receptor for advanced glycation endproducts (RAGE) is only present in mammals, and belongs to a family of cell adhesion molecules (CAMs)

The nocturnal bottleneck and the evolution of activity patterns in mammals

Molecular evolution of UCP1 and the evolutionary history of mammalian non-shivering thermogenesis

Animal models of mechanisms of SARS-CoV-2 infection and COVID-19 pathology

A mouse model of SARS-CoV-2 infection and pathogenesis

The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice

SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function

Development of Azeliragon, an oral small molecule antagonist of the receptor for advanced glycation endproducts, for the potential slowing of loss of cognition in mild Alzheimer's disease

Long-term renal effects of a neutralizing RAGE antibody in obese type 2 diabetic mice

Combinatorial library of improved peptide aptamers, CLIPs to inhibit RAGE signal transduction in mammalian cells

Advanced glycation end product recognition by the receptor for AGEs

Binding of S100 proteins to RAGE: an update

Interaction of the RAGE cytoplasmic domain with diaphanous-1 is required for ligand-stimulated cellular migration through activation of Rac1 and Cdc42

Signal transduction in receptor for advanced glycation end products (RAGE): solution structure of C-terminal rage (ctRAGE) and its binding to mDia1

Small molecule inhibition of ligand-stimulated RAGE-DIAPH1 signal transduction

Formin mDia1 mediates vascular remodeling via integration of oxidative and signal transduction pathways

The formin, DIAPH1, is a key modulator of myocardial ischemia/reperfusion injury

Deletion of the formin Diaph1 protects from structural and functional abnormalities in the murine diabetic kidney

Rho GTPases and actomyosin: partners in regulating epithelial cell-cell junction structure and function

Formins as effector proteins of Rho GTPases

Formins in cell signaling